Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the *Aegis Virtual Conference* on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live. The registration link to access the live presentation is included below and is also available at the Events section of the Chemomab website.
*Chemomab Presentation at 2024 Aegis Virtual Conference*
*Date:* May 7, 2024
*Time:* 9:00 am ET
*Venue:* Virtual
*Format:* Live webcast presentation
*Registration:* https://us02web.zoom.us/meeting/register/tZMkd-2trzIsHNTrU4RNyTw2dYX2Pqs_t-o8
*Information:* info@aegiscap.com
*About Chemomab Therapeutics Ltd.*
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information about Chemomab, visit chemomab.com.
*Contacts:*
*Media and Investors*:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com